8 Week Multi-site Study of MYDAYIS® for Bipolar Depression


About this study

The purpose of this study is to assess the effectiveness and safety of MYDAYIS® as an augmentation agent for bipolar depression.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Adults between 18 and 65 years of age.
  • Bipolar I or II disorder as confirmed by structured clinical interview for DSM-IV-TR.
  • Major depressive episode unresponsive to steady and stable (i.e., at least 2 weeks) mood stabilization (e.g., lithium, valproate, lamotrigine, carbamazepine/oxcarbamazepine, and/or atypical antipsychotic therapy) and non-psychotropic medication.
  • Antidepressant therapy is allowed in the study as long as patients are also on a mood stabilizer. Patients will be enrolled provided that any needed modifications to the antidepressant would be made at least two weeks prior to randomization.
  • Patients receiving psychotherapy will be allowed to be randomized provided therapy frequency does not change during the 8-week blinded phase.  
  • Symptom severity score on the Quick Inventory for Depressive Symptomatology – Clinician (QIDS-C16) ≥ 9, and the Clinical Global Impression for Bipolar Illness (CGI-BP) Depression Severity Scale ≥ 3.
  • Patients on stimulants for comorbid attention deficit disorder (ADHD) and/or binge eating disorder (BED) will be enrolled provided that the stimulant can be tapered and discontinued at least one week prior to randomization; symptom severity inclusion criteria must be met again prior to randomization.
  • Patients with a prescribed opiate (e.g.. hydroxicodone) or other pain intervention for acute or chronic pain management will be allowed provided they:
    • use a prescribed opiate or other pain intervention at a recommendation dose and established duration;
    • show no evidence of prescription misuse;
    • do not meet abuse or dependence criteria by SCID;
    • no known significant pharmacological interactions.
  • Ability to travel for the assessment visits.  

Exclusion Criteria:

  • Inability to provide written informed consent.
  • Inability to understand English.
  • Score less than 86% correct (i.e., one wrong) on comprehension assessment that reviews study goals.
  • Clinically significant signs of acute suicidality from any of the following assessments:
    • Response of > 2 on question #12 of QIDS-C; or
    •  Response = 3 on the SCID Module A- #A19.
  • Suicide attempt within the past year.
  • Concomitant treatment with monoamine oxidase inhibitors (MAOIs); also, within 14 days following discontinuation of treatment with a monoamine oxidase inhibitor.
  • Baseline Young Mania Rating Scale (YMRS) score ≥ 12.
  • Patients with active psychosis (measured by a score > 4 on YMRS question #8) or a diagnosis of schizophrenia, schizoaffective disorder, delusional, or schizophreniform disorder identified by structured clinical interview for DSM-IV-TR.
  • Active abuse or dependence of alcohol, opiates, or cannabis (nicotine dependence will be an exception) by structured clinical interview for DSM-IV-TR; patients meeting full remission for at least 3 months can be randomized. 
  • Positive toxicology screen for drugs of abuse (i.e., cocaine, methamphetamine, illegal opiates).
  • Positive toxicology screen for cannabis and a cannabis use disorder by structured clinical interview for DSM-IV-TR.  Participants who use cannabis for recreational or medicinal purposes and fail the toxicology screen can potentially be included in the study only if they take the CUDIT-R and score a 12 or less.
  • Known lifetime history of cocaine or methamphetamine abuse or dependence identified by structured clinical interview for DSM-IV-TR.
  • Active stimulant prescription abuse or dependence by structured clinical interview for DSM-IV-TR; patients meeting full remission for at least 6 months can be randomized.
  • Known lifetime history of stimulant-induced mania.
  • Known hypersensitivity, such as angioedema or anaphylaxis, to amphetamines or other ingredients of MYDAYIS.
  • Clinically unstable medical disease.
  • Known history of a structural cardiac abnormality, cardiomyopathy, serious heart rhythm abnormality, coronary artery disease, stroke, or other serious cardiovascular problems.
  • ECG with clinically significant arrhythmias, conduction abnormalities, or voltage criteria met for left ventricular hypertrophy (unless cleared by cardiology consultation).
  • Uncontrolled hypertension (> 160/100) or tachycardia (heart rate > 110).
  • History of grand mal seizure; history of febrile seizure as infant permitted.
  • Established vasculopathy or history of Raynaud’s phenomena.
  • Narrow angle glaucoma.
  • Chronic kidney disease (CKD) > stage IIIa (GFR 40-59).
  • Tourette syndrome.
  • Women who are pregnant, lactating or of child-bearing potential not using at least one adequate contraceptive measure (i.e., hormonal contraception-birth control pills, intrauterine devices (IUD), tubal ligation or condoms during sexual intercourse).
  • Current positive test for SARS-CoV-2; those with previous COVID-19 illness and those who test positive for SARS-CoV-2 any time after starting study drug or placebo will be included.
  • Otherwise excluded for administrative reasons and/or clinician judgment.

Eligibility last updated 3/22/22. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Mark Frye, M.D.

Open for enrollment

Contact information:

Monica Walton CCRP



Austin, Minn.

Mayo Clinic principal investigator

Ashok Seshadri, M.D.

Open for enrollment

Contact information:

Cynthia Stoppel CCRP

(507) 284-5914


More information


Publications are currently not available

Mayo Clinic Footer